| scholarly article | Q13442814 |
| P2093 | author name string | Jung-Soo Han | |
| Se-Young Choi | |||
| Yeon Ju Kim | |||
| Soo-Ryoon Ryoo | |||
| Ilho Ha | |||
| Jun-Seo Goo | |||
| Woo-Joo Song | |||
| Han-Saem Choi | |||
| Hey Kyeong Jeong | |||
| Kyoung-Jin Ahn | |||
| P433 | issue | 3 | |
| P921 | main subject | synaptic plasticity | Q1551556 |
| P304 | page(s) | 463-472 | |
| P577 | publication date | 2006-02-07 | |
| P1433 | published in | Neurobiology of Disease | Q15716606 |
| P1476 | title | DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects | |
| P478 | volume | 22 |
| Q28828212 | A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition |
| Q33830989 | A de novo convergence of autism genetics and molecular neuroscience |
| Q33452667 | A mouse embryonic stem cell bank for inducible overexpression of human chromosome 21 genes |
| Q30495192 | A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions |
| Q96576760 | A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay |
| Q37274100 | A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases |
| Q34280119 | Activity-dependent facilitation of Synaptojanin and synaptic vesicle recycling by the Minibrain kinase |
| Q42327736 | An ELISA DYRK1A non-radioactive kinase assay suitable for the characterization of inhibitors |
| Q37543845 | Aneuploidy: from a physiological mechanism of variance to Down syndrome |
| Q38104700 | Autism spectrum disorders: The quest for genetic syndromes |
| Q48321023 | Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development |
| Q26853662 | Challenges to congenital genetic disorders with “RNA-targeting” chemical compounds |
| Q33325766 | Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1. |
| Q83120929 | Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6 |
| Q55178268 | Cognitive Disorders: Impairment, Aging, and Dementia |
| Q59127645 | Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A |
| Q36581939 | Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1) |
| Q58551676 | DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome |
| Q43655626 | DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation |
| Q42033560 | DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome |
| Q64229393 | DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169 |
| Q26745413 | DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome |
| Q40074162 | DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease |
| Q34359769 | DYRK1A-mediated phosphorylation of GluN2A at Ser(1048) regulates the surface expression and channel activity of GluN1/GluN2A receptors |
| Q38866748 | DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis |
| Q39929463 | DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia |
| Q38865366 | Dementia in Down's syndrome |
| Q27665397 | Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A |
| Q37160637 | Differential Effects of Olanzapine and Haloperidol on MK-801-induced Memory Impairment in Mice |
| Q82875656 | Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay |
| Q45982836 | Domains of genome-wide gene expression dysregulation in Down's syndrome. |
| Q48351743 | Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A(+/-). |
| Q36681400 | Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21. |
| Q34964947 | Down syndrome--recent progress and future prospects |
| Q22241596 | Down syndrome: searching for the genetic culprits |
| Q48287894 | Down syndrome: the brain in trisomic mode |
| Q41242822 | Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D |
| Q48730272 | Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. |
| Q34559285 | Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome |
| Q48052891 | Dyrk1A negatively regulates the actin cytoskeleton through threonine phosphorylation of N-WASP |
| Q37347577 | Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells |
| Q33674369 | Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice |
| Q34181652 | Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells |
| Q24324114 | Dyrk1A-mediated phosphorylation of RCAN1 promotes the formation of insoluble RCAN1 aggregates |
| Q37507511 | E3 Ligase SCFβTrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells |
| Q37179205 | Editing of the serotonin 2C receptor pre-mRNA: Effects of the Morris Water Maze |
| Q48709346 | Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice |
| Q30497997 | Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. |
| Q34084791 | Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome |
| Q33595525 | Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). |
| Q37580743 | Function and regulation of Dyrk1A: towards understanding Down syndrome |
| Q38100616 | Functional implications of hippocampal adult neurogenesis in intellectual disabilities |
| Q36437976 | Gene Dosage-Dependent Association of DYRK1A With the Cytoskeleton in the Brain and Lymphocytes of Down Syndrome Patients |
| Q42102299 | Genetic analysis of Down syndrome facilitated by mouse chromosome engineering. |
| Q33412381 | Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. |
| Q36407266 | HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase. |
| Q34708624 | Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) |
| Q35523826 | Harmine treatment enhances short-term memory in old rats: Dissociation of cognition and the ability to perform the procedural requirements of maze testing |
| Q36002979 | Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1 |
| Q33354112 | Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). |
| Q38973876 | Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome |
| Q42130064 | Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation |
| Q37912174 | Is it possible to improve neurodevelopmental abnormalities in Down syndrome? |
| Q37820722 | MNB/DYRK1A as a multiple regulator of neuronal development |
| Q33874584 | Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome |
| Q34372365 | Minibrain/Dyrk1a regulates food intake through the Sir2-FOXO-sNPF/NPY pathway in Drosophila and mammals |
| Q37591118 | Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. |
| Q93031982 | Moderate prenatal stress may buffer the impact of Superstorm Sandy on placental genes: Stress in Pregnancy (SIP) Study |
| Q36111546 | Molecular and Cellular Alterations in Down Syndrome: Toward the Identification of Targets for Therapeutics |
| Q37179196 | Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. |
| Q35661597 | Mouse models for Down syndrome-associated developmental cognitive disabilities |
| Q38931172 | Mouse models of Down syndrome: gene content and consequences |
| Q34794979 | NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect |
| Q37446150 | Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis |
| Q64076419 | Neuronal overexpression of Alzheimer's disease and Down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila |
| Q43102409 | Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons. |
| Q39249843 | Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome |
| Q42785129 | Overexpression of Dyrk1A causes the defects in synaptic vesicle endocytosis |
| Q36841753 | Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome |
| Q34133976 | Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome |
| Q38006083 | Pathways to cognitive deficits in Down syndrome |
| Q38006087 | Perturbation of dendritic protrusions in intellectual disability |
| Q35002968 | Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) |
| Q39319404 | Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11α. |
| Q30366940 | Prioritizing the development of mouse models for childhood brain disorders |
| Q22252566 | Prospects for Improving Brain Function in Individuals with Down Syndrome |
| Q38061634 | Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? |
| Q24339194 | Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation |
| Q46193918 | Rodent models in Down syndrome research: impact and future opportunities. |
| Q48622962 | Strain-independent global effect of hippocampal proteins in mice trained in the Morris water maze |
| Q46464782 | Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships |
| Q49788245 | Systematic Functional Characterization of Human 21st Chromosome Orthologs in Caenorhabditis elegans |
| Q30490193 | Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. |
| Q41696401 | Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits. |
| Q37361341 | The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome |
| Q33952905 | The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation |
| Q30445156 | The E3 ligase APC/C-Cdh1 is required for associative fear memory and long-term potentiation in the amygdala of adult mice |
| Q51961245 | The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development |
| Q49757490 | Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. |
| Q35838946 | Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome |
| Q36718950 | Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly |
| Q28478075 | β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites |
Search more.